Assertio Holdings, Inc. · NASDAQ:ASRT
Assertio — Citizens JMP Life Sciences Conference 2024
14 slides from Assertio's conference presentation, May 2024
Slide 1: Profitable Growth and Cash Flows from Commercial Pharmaceutical Assets
Profitable Growth and Cash Flows from Commercial Pharmaceutical Assets Nasdaq: ASRT May 2024
Slide 2: Disclaimers
Disclaimers The statements in this communication include forward-looking statements. Forward-looking statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs. Forward-looking sta
Slide 3: Assertio Holdings Overview
Assertio Holdings Overview • Commercial focus: Differentiated, widely known pharmaceutical assets with strong cash flows and IP protection • Market agnostic: Oncology, neurology, hospital and pain/inflammation Business Summary • Omni-channel: Contracting, market access, digital non-personal promotio
Slide 4: Diverse Commercial Assets Focused on Cash Generation
Diverse Commercial Assets Focused on Cash Generation IP Protection on Key Assets: Rolvedon 2039, Sympazan 2040, Otrexup 2031 Core Growth Assets Steady Cash Flow Assets The first long-acting myeloid Oral film formulation of clobazam Methotrexate Opioid-level relief in a growth factor in 20+ years wit
Slide 5: Rolvedon: Clinically Differentiated in a Large Addressable Market
Rolvedon: Clinically Differentiated in a Large Addressable Market • Decreases the incidence of infection in adult patients receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia • $1+ billion estimated market opportunity1, ~1/3 focused on
Slide 6: Lower Cost, Efficient Omni-Channel Sales Platform
Lower Cost, Efficient Omni-Channel Sales Platform Focused field sales team drives added value in new Low-cost NPP platform blends digital channels, remote oncology-specific growth opportunities virtual representatives and machine learning • Strong relationships with key oncology stakeholders • 30+ p
Slide 7: 2024 Priorities
2024 Priorities Grow net sales and Deliver profitable growth Acquire new assets to manage product life with positive cash flow expand and diversify the cycles platform • Grow Rolvedon • Leverage efficient oncology • Identify assets that further and Sympazan sales by field sales team and low-cost div
Slide 8: 2024 Business Development Criteria
2024 Business Development Criteria Assertio is seeking to acquire or license commercial assets that will further diversify and build its platform Commercial Patent Life Cash Flow and Profit Synergies or Exclusivity Accretive • Can be supported by • Increased durability of • Quantifiable growth our o
Slide 9: 1Q 2024 Results
1Q 2024 Results $31.9 M $18.5 M $7.4 M Net Product Sales SG&A Expense Adj. EBITDA -1.8% v PQ -22.9% v PQ +66.0% v PQ $7.5 M $80.7 M Operating Cash Flow Cash Balance +31.5% v PQ +9.9% v PQ • Rolvedon net sales +32% Q0Q – 5th consecutive quarter of demand growth • Completed Rolvedon same-day dosing tr
Slide 10: Full Year 2024 Outlook
Full Year 2024 Outlook FY 2024 Outlook(1) Additional Full-Year 2024 Outlook Comments: • Rolvedon sales approaching $60 million $110-125 M $20-30 M • Indocin sales of $18-$25 million • Adjusted operating expenses of $65-$70 million Net Product Sales Non-GAAP Adj EBITDA • End of 2024 cash balance of $
Slide 11: 2024 Priorities
2024 Priorities Grow net product sales and manage product life cycles Deliver profitable growth with positive cash flow Acquire new assets to expand and diversify the platform 11
Slide 12: Investor Contact
Investor Contact Matt Kreps of Darrow Associates IR for the Company [email protected] 12
Slide 13: Operating Results Full-Year 2022-2023
Operating Results Full-Year 2022-2023 For additional information referencing the schedules adjusting items, refer to the annual results announcement Form-8K on file with the Securities and Exchange Commission. 13
Slide 14: Non-GAAP EBITDA Reconciliation and Notes
Non-GAAP EBITDA Reconciliation and Notes (1) The fair value of the contingent consideration is remeasured each reporting period, with changes in the fair value resulting from changes in the underlying inputs being recognized as a benefit or expense in operating expenses until the contingent consider
Assertio Holdings — Citizens JMP Life Sciences Conference 2024 on 6ix